PCSK9 and fatty liver disease: In humans, it has been concluded that the severity of hepatic steatosis affects the correlation between circulating PCSK9 and liver fat content, with a possible impact of circulating PCSK9 in the early stages of NAFLD, but not in the late stages [113].